Our findings demonstrating the presence of cryptic HDGFL2 in both CSF and blood of individuals with ALS–FTD now provide direct evidence that loss of TDP-43 splicing repression occurs during early-stage disease, including the presymptomatic phase. The gene discussed is HDGFL2; the disease is frontotemporal dementia.